Cancer immunotherapy: Co-stimulatory agonists and co-inhibitory antagonists

Department of Haematology, UCL Cancer Institute, Paul O'Gorman Building, University College London, London, UK.
Clinical & Experimental Immunology (Impact Factor: 3.04). 08/2009; 157(1):9-19. DOI: 10.1111/j.1365-2249.2009.03912.x
Source: PubMed


The generation and maintenance of immune responses are controlled by both co-stimulatory and co-inhibitory signalling through T cell co-receptors, many of which belong to the immunoglobulin-like superfamily or the tumour necrosis factor receptor superfamily. Agonistic or antagonistic monoclonal antibodies targeting these co-receptors have the potential to enhance immunity. Furthermore, their activity on the immunosuppressive regulatory T cell populations which are prevalent within many tumours provides an additional rationale for their use as anti-cancer therapies. This review summarizes the interactions between cancer and the immune system, highlighting the ways in which these new classes of immunostimulatory antibodies might enhance anti-tumour immunity and summarizing early clinical experience with their use.

Download full-text


Available from: Sergio Andres Quezada, Oct 04, 2015
35 Reads
  • Source
    • "Early evidence for its potential as a target for enhancing antitumour immunity came from murine models (Leach et al, 1996), followed shortly thereafter by clinical evaluation of fully human anti-CTLA-4 antibodies. Objective responses as defined by Response Evaluation Criteria in Solid Tumours (RECIST) were documented in 10–15% of patients, though immune-related adverse events (IRAEs) involving a variety of tissues, including the gastrointestinal tract, were documented in 25–30% of cases treated at the higher doses (reviewed in Peggs et al, 2009a), highlighting the relatively narrow therapeutic index. Clinical responses appeared to correlate with the development of IRAEs, though this correlation was not absolute in either direction (Downey et al, 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The past few years have witnessed something of a renaissance in the field of cancer immunotherapy, relating largely to the clinical advances that have been associated with the development of monoclonal antibodies targeting the immune inhibitory co-receptors CTLA-4 and PD-1 and to the pursuit of genetically modified antigen-redirected adoptive T-cell therapies. These advances are based on a more substantial understanding of the factors restricting effective immune therapies that has been derived from the study of pre-clinical models of tumour growth in immune competent mice. Just as the recognition of the importance of positive co-stimulatory signaling has been instrumental to recent advances in the development of genetically modified antigen-specific adoptive cellular therapies, an increasing awareness of the ability of tumours to subvert multiple immune inhibitory pathways, effectively blunting the development or expansion of any anti-tumour immunity, is fostering the development of novel therapies that appear active as monotherapies but may achieve their greatest impact in combinatorial regimens. This mini-review will focus on attempts to target co-inhibitory members of the immunoglobulin superfamily.British Journal of Cancer advance online publication, 19 March 2013; doi:10.1038/bjc.2013.117
    British Journal of Cancer 03/2013; 108(8). DOI:10.1038/bjc.2013.117 · 4.84 Impact Factor
  • Immunotherapy 11/2009; 1(6):921-4. DOI:10.2217/imt.09.74 · 2.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Progress in the development of DNA vaccines and their delivery strategies has been made since their initial concept as a next generation vaccine. Since DNA vaccine includes non-infectious DNA parts of pathogens, it can't cause disease yet it closely mimic the natural process of infection and immune responses. Despite their early promising results of controlling infectious diseases and cancer in small animal models, DNA vaccines failed to display a level of immunogenicity required for combating these diseases in humans, possibly due to their lower protein expression levels. However, increasing evidence has shown that DNA vaccines are clinically well-tolerated and safe. Furthermore, one notable advantage of DNA vaccines includes convenient utilities of plasmid DNAs coding for antigens. For instance, any emerging pathogens could be prevented easily and timely by allowing the simple exchange of antigen-encoding genes. In this review, newly developed DNA vaccine strategies, including electroporation, which has emerged as a potent method for DNA delivery, targeting infectious diseases and cancer will be discussed with a focus on any on-going DNA vaccine trials or progress made pre-clinically and in clinics.
    Biomolecules and Therapeutics 01/2010; 18(1):1-15. DOI:10.4062/biomolther.2010.18.1.001 · 1.73 Impact Factor
Show more